| 注册
首页|期刊导航|中华医学杂志(英文版)|Impact of baseline CD4~+ T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study

Impact of baseline CD4~+ T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study

LIU Zheng-yin GUO Fu-ping HAN Yang QIU Zhi-feng ZUO Ling-yan LI Yan-ling LI Tai-sheng

中华医学杂志(英文版)2009,Vol.122Issue(20):2497-2502,6.
中华医学杂志(英文版)2009,Vol.122Issue(20):2497-2502,6.DOI:10.3760/cma.j.issn.0366-6999.2009.20.018

Impact of baseline CD4~+ T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study

Impact of baseline CD4~+ T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study

LIU Zheng-yin 1GUO Fu-ping 1HAN Yang 1QIU Zhi-feng 1ZUO Ling-yan 1LI Yan-ling 1LI Tai-sheng1

作者信息

  • 1. Peking Union Medical College Hospital
  • 折叠

摘要

Abstract

Background CD4~+ T cell counts have been used as the indicator of human immunodeficiency virus type 1 (HIV-1) disease progression and thereby to determine when to start highly active antiretroviral therapy (HAART). Whether and how the baseline CD4~+T cell count affects the immunological and viral responses or adverse reactions to nevirapine (NVP)-containing HAART in Chinese HIV-1 infected adults remain to be characterized.Methods One hundred and ninety-eight HIV-seropositive antiretroviral therapy (ART)-naive subjects were enrolled into a prospective study from 2005 to 2007. Data were analyzed by groups based on baseline CD4~+T cell counts either between 100-200 cells/μl or 201-350 cells/pl. Viral responses, immunologic responses and adverse events were monitored at baseline and at weeks 4, 12, 24, 36, 52, 68, 84, 100.Results Eighty-six and 112 subjects ranged their CD4~+T cell counts 100-200 cells/μl and 201-350 cells/μl, respectively.The pre-HAART viral load in CD4 201-350 cells/μl group was significantly lower than that in CD4 100-200 cells/μl group (P=0.000). After treatment, no significant differences were observed between these two groups either in the plasma viral load (pVL) or in the viral response rate calculated as the percentage of pVL less than 50 copies/μl or less than 400 copies/ml. The CD4~+T cell counts were statistically higher in the 201-350 group during the entire follow-ups (P<0.01) though CD4~+ T cell count increases were similar in these two groups. After 100-week treatment, the median of CD4~+ T cell counts were increased to 331 cells/μl for CD4 100-200 cells/μl group and to 462 cells/μl for CD4 201-350 cells/μl group.Only a slightly higher incidence of nausea was observed in CD4 201-350 cells/μl group (P=0.05) among all adverse reactions, including rash and liver function abnormality.Conclusions The pVLs and viral response rates are unlikely to be associated with the baseline CD4~+T cell counts. Initiating HAART in Chinese HIV-1 infected patients with higher baseline CD4~+T cell counts could result in higher total CD4~+ T cell counts thereby achieve a better immune recovery. These results support current guidelines to start HAART at a threshold of 350 cells/μl.

关键词

human immunodeficiency virus/ acquired immunodeficiency syndrome/highly active antiretroviral therapy/ CD4~+ T cell counts/ nevirapine

Key words

human immunodeficiency virus/ acquired immunodeficiency syndrome/highly active antiretroviral therapy/ CD4~+ T cell counts/ nevirapine

分类

医药卫生

引用本文复制引用

LIU Zheng-yin,GUO Fu-ping,HAN Yang,QIU Zhi-feng,ZUO Ling-yan,LI Yan-ling,LI Tai-sheng..Impact of baseline CD4~+ T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study[J].中华医学杂志(英文版),2009,122(20):2497-2502,6.

基金项目

This study was supported by the grants from the National Key Technologies R&D Program for the 11th Five-year Plan (No. 2008ZX10001-006), Ministry of Health Clinical HIV/AIDS Research Grant (2007-2009) and Beijing Science and Technology Program Fund (No. D0906003040491). (No. 2008ZX10001-006)

中华医学杂志(英文版)

OACSTPCDMEDLINESCI

0366-6999

访问量0
|
下载量0
段落导航相关论文